Preferential measures on bioequivalence-proven items eyed

The Ministry of Health and Welfare (MOHW) announced on December 31 that it revised the calculation criteria of drug ceiling price (Attachment No. 1) concerning the determination and adjustment of new medical technology, to this effect that the prices of bioequivalence-accredited copy products, as recognized by a commissioner of the Korea Food and Drug Administration, will be in the level of 80 ...